Can’t Sleep – Capsules

Endocannabinoid System (ECS) Supplement

Calm the Brain. Support Restorative Sleep.

Can’t Sleep – Capsules were developed as part of the ECS Therapy line of Endocannabinoid System (ECS) supplements, designed to support relaxation pathways and healthy sleep cycles through a targeted ECS modulation strategy.

Our high-potency formulation combines cannabinoids, calming botanicals, amino acids, minerals, and terpenes carefully selected to support neurological relaxation and sleep signaling.

Backed by science. Field tested ’til approved

One of the key cannabinoids used in this formulation is CBN (cannabinol). In nature, CBN forms when THC naturally oxidizes and converts over time. Unlike THC, CBN is non-intoxicating, yet research and clinical observations have associated it with sleep-supportive properties.

CBD helps support nervous system balance and stress signaling pathways.

CBG has been studied for its role in supporting neurological calmness and relaxation signaling.

CBC contributes additional calming support and may help address physical discomfort that can interfere with restful sleep.

Together, these cannabinoids work through the Endocannabinoid System,
supporting the body’s natural signaling network involved in relaxation, sleep regulation, and neurological balance.

Why the Endocannabinoid System Matters for Sleep

Endocannabinoid System (ECS) dysfunction plays a central role in disrupting sleep architecture and neurological balance.

Research published through the National Institutes of Health (NIH) has shown that disruptions in ECS signaling can alter the balance of key nendocannabinoids including:

Anandamide (AEA)

2-Arachidonoylglycerol (2-AG)

These endogenous signaling molecules help regulate circadian rhythm activity, sleep-wake balance, and neurological relaxation.
Scientific literature has associated disruption of AEA and 2-AG signaling
with:

The ECS also interacts with the brain’s suprachiasmatic nucleus (SCN), the central regulator of circadian rhythm.

When ECS signaling becomes dysregulated, the body may struggle to maintain healthy sleep cycles.

The ECS Therapy 3-Layer Modulation Strategy

ECS Therapy formulations are developed using a three-layer modulation strategy designed to support multiple biological pathways involved in relaxation and sleep regulation.

Layer 1 — Cannabinoids

Primary ECS Signaling Support

Cannabinoids interact with the body’s CB1 and CB2 receptors, helping support signaling pathways involved in relaxation and sleep regulation.

Sleep regulation is closely tied to the balance of the body’s primary endocannabinoids — anandamide (AEA) and 2-arachidonoylglycerol (2 AG).

Published research has shown that disruption of these signaling molecules is associated with sleep fragmentation and impaired sleep architecture.

Research has also reported that CBD inhibits FAAH (fatty acid amide hydrolase), the enzyme responsible for breaking down anandamide. By slowing FAAH activity, studies suggest anandamide signaling may remain active longer, supporting ECS signaling pathways involved in relaxation and sleep readiness.

These cannabinoids were selected to support ECS signaling associated with relaxation, sleep onset, and nervous system balance.

Cannabinoid Profile:

Layer 2 — Terpenes

Neurological Modulators

Terpenes, the aromatic compounds in plants, have been reported in the scientific literature to aid sleep by acting as sedatives and by supporting activity within the Endocannabinoid System (ECS) to promote relaxation.

Published research and observations within cannabinoid science describe what is often referred to as the entourage effect, where terpenes modulate cannabinoid activity and influence neurological signaling pathways. Some studies have suggested that certain terpenes may influence blood-brain barrier permeability and support calming neurotransmitter systems such as GABA, both of which are associated with relaxation and sleep readiness.

These terpenes were specifically selected due to their studied associations with relaxation, calming neurological activity, and sleep support.

Proprietary Terpene Complex:

Layer 3 — Calming Botanical Pathways

Pathway Signaling Support

The combination of valerian root extract, magnolia bark, apigenin, L theanine, nano kava extract, and magnesium glycinate supports relaxation through multiple complementary pathways associated with neurological calmness and sleep readiness.

Research literature has associated these compounds with support for:

Working together, these ingredients provide multi-pathway relaxation support, helping the body transition into a more relaxed state before sleep.

Botanical Complex

Suggested Use

START HERE

ECS Therapy 7-Day Evaluation Program — $35 plus shipping

Experience a formulation designed to support multiple pathways to comfort and
recovery.

The evaluation program allows individuals to explore how Endocannabinoid
System (ECS) supplements may support your body’s natural balance.

Join the Movement

Monthly Subscription

Save 15% + Free Shipping

$67.15

/mon

One-time Purchase

No commitment

$79.00

30-day money-back guarantee. Cancel any time.

Access Options

ECS Member Access

Non-Member Access

ECS Therapy™ 7-Day Evaluation Program

Our formulations have been refined through over eight years of research, formulation development, and real-world field testing.

Because each individual responds differently to Endocannabinoid System (ECS)
supplements, we created the ECS Therapy 7-Day Evaluation Program.

This program allows individuals to explore how ECS modulation may support their body’s natural balance.

Each evaluation package includes:

ECS Therapy Quality Standards

Every ECS Therapy formula is produced with strict quality standards.

Disclaimer !

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The Scientists Who Made This Possible

Dr. Raphael Mechoulam

The Godfather of Cannabis Research Isolated and synthesized THC and CBD, fundamentally reshaping our understanding of cannabinoids and discovering the endocannabinoid system itself. Without Dr. Mechoulam’s foundational work, none of this would exist. When he responded to my email in May 2019 with his clinical trial data, he gave me the blueprint for what ECS modulation could be.

Dr. Ethan Russo

Demonstrated that terpenes and cannabinoids work synergistically, proving that “the sum of all the parts” is greater than isolated components. His 2016 paper “Beyond Cannabis: plants and the endocannabinoid system” expanded the conversation beyond a single plant—showing that the ECS is larger than cannabis alone. His research directly supports what we’re doing.

Dr. Sue Sisley

The Advocate for Real-World Science Conducted the first FDA-approved randomized controlled trial assessing the safety and efficacy of cannabis in military veterans with PTSD, fighting federal barriers to conduct rigorous clinical research on whole-plant medicine. Dr. Sisley’s persistence—filing lawsuits against the DEA, breaking the federal monopoly on cannabis research—proved that real-world cannabinoid research matters more than pharmaceutical shortcuts.

Dr. William Courtney

Pioneer of Raw Cannabinoid Research First to systematically study THCA, CBDA, and other raw cannabinoid precursors, demonstrating that cannabinoids in their natural (non-heated) form have therapeutic potential superior to decarboxylated forms at lower doses. His work expanded my understanding of the complete cannabinoid spectrum and why Phase 2 formulations will use raw cannabinoid compounds alongside decarboxylated forms.

Dr. Shimon Ben-Shabat

Co-Discoverer of the Entourage Effect Collaborated with Dr. Mechoulam in 1998 to propose the concept that compounds work better together than in isolation. This foundational principle—botanical synergy—is the entire philosophy behind ECS Therapy’s three-layer approach.

Dr. Dustin Sulak

Pioneer of Clinical Cannabinoid Medicine & Patient-Centered Education Founded Integr8 Health (serving 8,000+ patients with medical cannabis) and Healer.com, providing rigorous education on the endocannabinoid system and clinical cannabinoid protocols. His work bridges the gap between scientific research and real-world patient application. I studied his comprehensive courses on ECS science, cannabinoid dosing, and condition-specific treatment guidelines—education that became foundational to how I approach formulation and patient outcomes. Dr. Sulak’s emphasis on “using the correct dose” and understanding the ECS at every level directly informed ECS Therapy’s precision approach.